Search
Remdesivir
go.drugbank.com/drugs/DB14761ApprovedInvestigational[L18438] Remdesivir was also approved by the European Commission on July 3, 2020. … [A191427, A198810] Remdesivir was confirmed as a non-obligate chain terminator of RdRp from SARS-CoV-2 and the related SARS-CoV and MERS-CoV,[A222398] and has been investigated in multiple COVID-19 clinical
Escitalopram
go.drugbank.com/drugs/DB01175ApprovedInvestigationalthe vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as … A39738,A185819] Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as
Products: PMS-escitalopramUpadacitinib
go.drugbank.com/drugs/DB15091ApprovedInvestigational[A189168] To reduce dose-related toxicity (as seen with some pan-JAK inhibitors) without significantly affecting efficacy, more selective JAK1 inhibitors, upadacitinib and [filgotinib], were developed. … [L10896] In December 2019, it was additionally approved by the European Commission and Health Canada.[L10899,L42540] Upadacitinib is marketed under the brand name RINVOQ for oral administration.
Caffeine
go.drugbank.com/drugs/DB00201ApprovedInvestigational[T716] The caffeine citrate injection, used for apnea of the premature newborn, was initially approved by the FDA in 1999.
Mixtures: PAX FORTE, PAX FORTE®Tepotinib
go.drugbank.com/drugs/DB15133ApprovedInvestigationalIn February 2022, tepotinib was approved for use in Europe.[L42200] … Tepotinib was first approved in Japan in March 2020 for the treatment of non-small cell lung cancers (NSCLC) with _MET_ alterations, and was subsequently granted accelerated approval by the US FDA in February
Favipiravir
go.drugbank.com/drugs/DB12466ApprovedInvestigational[A191721,L12090] Favipiravir has been investigated for the treatment of life-threatening pathogens such as Ebola virus, Lassa virus, and now COVID-19.[A191724,A191958,A191961] … Discovered by Toyama Chemical Co., Ltd. in Japan, favipiravir is a modified pyrazine analog that was initially approved for therapeutic use in resistant cases of influenza.
Buprenorphine
go.drugbank.com/drugs/DB00921ApprovedIllicitInvestigationalVet approvedas [heroin], [oxycodone], or [methadone]. … [A186289,L46571] Buprenorphine has poor gastrointestinal absorption and is therefore formulated as a sublingual tablet.
Mixtures: PMS-buprenorphine-naloxone, PMS-buprenorphine-naloxoneDarvadstrocel
go.drugbank.com/drugs/DB16581ApprovedInvestigationalWithdrawn[L39759] It is the first mesenchymal stem cell therapy approved in Europe for this therapeutic indication. … [A244524] Darvadstrocel was first approved by the European Commission on March 23, 2018, under the brand name Alofisel.
Doxylamine
go.drugbank.com/drugs/DB00366ApprovedInvestigationalVet approvedIt is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism.
Mixtures: PMS-doxylamine-pyridoxineTrametinib
go.drugbank.com/drugs/DB08911ApprovedInvestigational[A258298] It was later approved by Health Canada on July 18, 2013 [L45588] and by the European Commission on June 30, 2014. … [L45583] Trametinib is currently approved to treat a variety of cancers with BRAF mutations, such as non-small cell lung cancer and thyroid cancer, as monotherapy or in combination with [dabrafenib], a